Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, has scheduled its first fiscal quarter 2026 financial results conference call for Tuesday, August 12, 2025, at 4:30 PM ET.
The company will discuss its financial performance for the quarter ended June 30, 2025. Investors can access the conference call through domestic (1-877-407-0784) or international (1-201-689-8560) dial-in numbers using conference ID 13754769. A webcast will be available through the company's website, with a replay accessible after the call.
Beyond Air (NASDAQ: XAIR), un'azienda biotecnologica e di dispositivi medici in fase commerciale specializzata nei trattamenti a base di ossido nitrico (NO), ha programmato la sua prima conferenza telefonica sui risultati finanziari del primo trimestre fiscale 2026 per martedì 12 agosto 2025, alle 16:30 ET.
L'azienda discuterà le performance finanziarie relative al trimestre terminato il 30 giugno 2025. Gli investitori potranno partecipare alla conferenza telefonica chiamando i numeri nazionali (1-877-407-0784) o internazionali (1-201-689-8560) e inserendo il codice ID conferenza 13754769. Sarà inoltre disponibile una diretta web tramite il sito aziendale, con la possibilità di riascoltare la registrazione dopo la chiamata.
Beyond Air (NASDAQ: XAIR), una empresa de dispositivos médicos y biotecnología en etapa comercial especializada en tratamientos con óxido nítrico (NO), ha programado su primera llamada de conferencia para presentar los resultados financieros del primer trimestre fiscal 2026 para el martes 12 de agosto de 2025 a las 4:30 PM ET.
La compañía discutirá su desempeño financiero del trimestre terminado el 30 de junio de 2025. Los inversores podrán acceder a la llamada a través de los números nacionales (1-877-407-0784) o internacionales (1-201-689-8560) utilizando el ID de conferencia 13754769. Habrá una transmisión en vivo disponible en el sitio web de la empresa, con una repetición accesible después de la llamada.
Beyond Air (NASDAQ: XAIR)는 산화질소(NO) 치료를 전문으로 하는 상업 단계의 의료기기 및 생명공학 회사로, 2026 회계연도 1분기 재무실적 컨퍼런스 콜을 2025년 8월 12일 화요일 오후 4시 30분(동부시간)에 개최할 예정입니다.
회사는 2025년 6월 30일 종료된 분기의 재무 성과를 논의할 예정입니다. 투자자들은 국내 전화번호(1-877-407-0784) 또는 국제 전화번호(1-201-689-8560)를 통해 컨퍼런스 ID 13754769를 사용하여 컨퍼런스 콜에 참여할 수 있습니다. 회사 웹사이트를 통해 웹캐스트가 제공되며, 콜 종료 후 다시 듣기도 가능합니다.
Beyond Air (NASDAQ : XAIR), une société de dispositifs médicaux et biopharmaceutique en phase commerciale spécialisée dans les traitements à base d’oxyde nitrique (NO), a programmé sa première conférence téléphonique sur les résultats financiers du premier trimestre fiscal 2026 pour le mardi 12 août 2025 à 16h30 (heure de l’Est).
La société discutera de ses performances financières pour le trimestre clos le 30 juin 2025. Les investisseurs pourront accéder à la conférence téléphonique via les numéros d’appel nationaux (1-877-407-0784) ou internationaux (1-201-689-8560) en utilisant l’ID de conférence 13754769. Un webcast sera disponible sur le site web de la société, avec une rediffusion accessible après l’appel.
Beyond Air (NASDAQ: XAIR), ein medizinisches Geräte- und Biopharmaunternehmen in der kommerziellen Phase, das sich auf Stickstoffmonoxid (NO)-Behandlungen spezialisiert hat, hat seine Telefonkonferenz zu den Finanzergebnissen des ersten Quartals des Geschäftsjahres 2026 für Dienstag, den 12. August 2025, um 16:30 Uhr ET angesetzt.
Das Unternehmen wird seine finanzielle Leistung für das Quartal zum 30. Juni 2025 besprechen. Investoren können an der Telefonkonferenz über nationale (1-877-407-0784) oder internationale (1-201-689-8560) Einwahlnummern mit der Konferenz-ID 13754769 teilnehmen. Ein Webcast wird über die Unternehmenswebsite verfügbar sein, mit einer Aufzeichnung, die nach dem Anruf abrufbar ist.
- None.
- None.
GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its first fiscal quarter ended June 30, 2025 on Tuesday, August 12, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.
| Conference Call & Webcast | |
| Tuesday, August 12th @ 4:30 PM ET | |
| Domestic: | 1-877-407-0784 |
| International: | 1-201-689-8560 |
| Conference ID: | 13754769 |
| Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call. | |
About Beyond Air®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
When will Beyond Air (XAIR) report Q1 2026 earnings?
How can I access Beyond Air's Q1 2026 earnings call?
What is Beyond Air's (XAIR) main business focus?
Will there be a replay available for Beyond Air's Q1 2026 earnings call?
